HOUSTON, Sept. 24, 2018 /PRNewswire/ — SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of spinal discs using Human Dermal Fibroblasts, today announced it will be showcasing its fibroblast-based cell therapy product CybroCell at the North American Spine Society (NASS) 2018 Annual Meeting Sept. 26 – 29 in Los Angeles.
The company recently published data in The Spine Journal that suggest fibroblast cell therapies can prevent the degeneration and promote the regeneration of spinal discs. This publication is available at https://www.thespinejournalonline.com/article/S1529-9430(18)31093-3/. The transplantation of dermal fibroblasts was found to significantly increase the markers of disc regeneration and supported the hypothesis that the intervertebral disc is immune privileged.
“The data we’re sharing at NASS demonstrate that CybroCell has the potential to fundamentally change the way back pain is treated,” said Pete O’Heeron, SpinalCyte Chief Executive Officer. “With our strong intellectual property position and ongoing Phase 1/Phase 2 trials, SpinalCyte has the potential to relieve pain and improve function for millions who currently have no viable treatment options.”
About Degenerative Disc Disease
Degenerative disc disease (DDD) is a condition in which a patient’s spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.
About CybroCell
CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated preliminary six-month data whereby 83% of patients had an increase or no change in disc height.
About SpinalCyte
Based in Houston, Texas, SpinalCyte, LLC is a regenerative medicine company developing an innovative solution for spinal replacement using human dermal fibroblasts. Currently, SpinalCyte holds 33 U.S. and international issued patents and has filed for an additional 43 patents pending. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com.
Contact:
David Schull or Ned Berkowitz
Russo Partners LLC
858-717-2310
646-942-5629
david.schull@russopartnersllc.com
ned.berkowitz@russopartnersllc.com
SOURCE SpinalCyte, LLC
